{name}
{subtitle}
A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
city
~15 mi. (Brescia, Italy, +260 more cities)
facility
ASST DEGLI SPEDALI CIVILI DI BRESCIA; Oncologia Medica
biomarker
ERBB2 Amplification, +1 more biomarker
drug type
immunotherapy, +1 more type
Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
city
~15 mi. (Brescia, Italy, +141 more cities)
facility
GSK Investigational Site
drug type
chemotherapy, +1 more type
A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Patients With PIK3CA-Mutant, Hormone Receptor-Positive, Her2-Negative, Locally Advanced or Metastatic Breast Cancer
city
~15 mi. (Brescia, Italy, +186 more cities)
facility
Az. Osp. Spedali Civili; Divisione Di Oncologia - Iii Medicina
biomarker
ER Positive, +3 more biomarkers
drug
fulvestrant, +2 more drugs
drug type
hormone therapy, +1 more type
A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer
city
~34 mi. (Bergamo, Italy, +383 more cities)
facility
Azienda Ospedaliera Papa Giovanni XXIII
biomarker
ER Negative, +2 more biomarkers
drug
atezolizumab, +4 more drugs
drug type
chemotherapy, +1 more type
A Study of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a Treatment for Participants With Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Advanced (LABC) or Metastatic Breast Cancer (MBC)
city
~34 mi. (Bergamo, Italy, +115 more cities)
facility
Asst Papa Giovanni XXIII
biomarker
ERBB2 Amplification, +7 more biomarkers
drug type
immunotherapy, +1 more type